Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC ...

Najat Khan, CEO, opened by stating that Recursion is at an important inflection point, harnessing its integrated AI-driven platform to "translate insights into evidence; evidence that this platform, ...

Just-released Version 1.113 of Microsoft’s Visual Studio Code editor emphasizes improvements ranging from chat customizations ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

To own Recursion, you need to believe its AI-native platform can keep turning data into real clinical wins and eventual products, not just partnerships. The FAP proof of concept sharpens that near ...

The campaign, observed in February 2026, has been assessed to share overlaps with a prior campaign mounted by Laundry Bear, a ...

DRILLAPP JavaScript backdoor targets Ukraine in Feb 2026, abusing Edge debugging features to spy via camera, microphone, and ...